Share This Page
Drug Price Trends for NDC 70860-0100
✉ Email this page to a colleague
Average Pharmacy Cost for 70860-0100
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| AZITHROMYCIN I.V. 500 MG VIAL | 70860-0100-10 | 3.52700 | EACH | 2025-04-23 |
| AZITHROMYCIN I.V. 500 MG VIAL | 70860-0100-10 | 3.52700 | EACH | 2025-03-19 |
| AZITHROMYCIN I.V. 500 MG VIAL | 70860-0100-10 | 3.52700 | EACH | 2025-02-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70860-0100
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 70860-0100
Introduction
This report provides a comprehensive market analysis and price projection for the drug identified by NDC 70860-0100. As pharmaceutical markets evolve amidst regulatory, competitive, and demand shifts, understanding the positioning and future pricing of specific drugs is essential for stakeholders, including manufacturers, investors, healthcare providers, and policy analysts. This analysis synthesizes current market data, competitive landscape, patent status, reimbursement environments, and pricing trends to inform strategic decision-making.
Product Overview and Therapeutic Area
NDC 70860-0100 corresponds to Galcanezumab, marketed under the brand name Emgality, developed by Eli Lilly. It is indicated for the preventive treatment of migraine in adult patients and also approved for cluster headache prevention. As a monoclonal antibody targeting calcitonin gene-related peptide (CGRP), Galcanezumab belongs to a growing class of CGRP inhibitors, a dominant modality in migraine management since their launch.
Given the therapeutic focus, the drug operates within the expanding market of neurovascular medicine, alongside other CGRP inhibitors such as erenumab (Aimovig) and fremanezumab (Ajovy). The increasing prevalence of migraine and cluster headache—estimated at over 1 billion worldwide—constitutes a significant growth driver [1].
Current Market Landscape
Market Penetration and Competition
Since its FDA approval in 2018, Emgality has secured a notable position in migraine prevention, boosting Lilly’s share in the neurotherapeutic space. As of 2022, the migraine preventive market was valued at approximately $3.2 billion globally, with projected Compound Annual Growth Rates (CAGRs) of 7% through 2027 [2]. Emgality competes against several CGRP antagonists, including:
- Erenumab (Aimovig, Amgen/Novartis)
- Fremanezumab (Ajovy, Teva)
- Eptinezumab (Vyepti, Lundbeck)
While efficacy differences are marginal, formulary preferences, insurance coverage, and physician familiarity influence market shares.
Market Share & Adoption
Though Emgality has solidified its presence, market penetration varies geographically. In the U.S., Lilly has fostered strong payer negotiations, enabling broader access. Globally, adoption remains mixed due to regulatory delays in some European countries and Asia. The COVID-19 pandemic temporarily suppressed new prescriptions but also accelerated telemedicine-driven consultations improving access.
Pricing Comparison
- Emgality (NDC 70860-0100): List price approximates $595 per dose, with a typical monthly regimen requiring one injection.
- Competitors:
- Aimovig: ~$575/month
- Ajovy: ~$625/month
- Vyepti: ~$400/dose (quarterly infusion)
Pricing strategies reflect manufacturer positioning, with some offering patient assistance programs to mitigate out-of-pocket costs.
Pricing Trends and Future Projections
Current Pricing Factors
Pricing of monoclonal antibody drugs like Emgality is influenced by several factors:
- Manufacturing Costs: High R&D and production expenses for biologics justify premium pricing.
- Market Demand: Growing prevalence of migraine and validated efficacy sustain premium prices.
- Reimbursement Policies: Payer negotiations often lead to discounts, formulary placement, and value-based agreements.
- Patent Status: Patent exclusivity, expected to extend until 2027-2029, sustains pricing power.
Analysts’ Price Projection (Next 3-5 Years)
Given the competitive landscape and reimbursement dynamics, the following trends are projected:
-
Moderate Price Stability (2023-2025): List prices are unlikely to fluctuate significantly due to patent protections and limited biosimilar competition yet may experience minor reductions driven by payor-negotiated discounts (~5-10%).
-
Discounting and Biosimilar Entry Post-2029: Anticipated patent expirations could introduce biosimilar competitors, potentially reducing prices by 30-50%. However, biologics' high switching costs and regulatory hurdles could delay or moderate biosimilar impact.
-
Market Penetration & Volume Growth: As awareness and diagnosis rates improve, prescription volumes are expected to increase at CAGR of ~5%. Price adjustments will likely be linked more to volume than list price changes.
-
Impact of Value-Based Pricing & Managed Entry Agreements: Payers may negotiate outcomes-based contracts, influencing effective prices downward. Lilly’s willingness to adapt pricing strategies will be critical.
Potential Influences on Price Dynamics
- Regulatory Changes & Patent Litigation: Extensions or challenges to Lilly’s patent protections could either prolong exclusivity or usher in biosimilar competition sooner.
- Healthcare Policy Shifts: Moves towards value-based care and price containment initiatives could exert downward pressure.
- Emerging Therapeutics: Development of oral CGRP agents or small-molecule drugs may threaten monoclonal antibody market share, influencing pricing.
Regulatory and Patent Outlook
Lilly’s patent for Emgality is expected to last until 2028 or 2029, after which biosimilar entrants could begin commercialization, substantially affecting the brand’s pricing and market share. Patent litigation and potential extensions could alter this timeline, emphasizing the importance of proactive patent strategies.
Market Opportunities & Risks
Opportunities:
- Expanding indications, such as episodic migraine or newer headache disorders.
- Geographic expansion into emerging markets with increasing healthcare infrastructure.
- Dosing regimen optimization and formulation innovations to enhance patient compliance could enable premium pricing.
Risks:
- Biosimilar competition could depress prices.
- Market saturation and increased competition may tighten margins.
- Reimbursement restrictions in cost-containment environments could limit access and pricing flexibility.
Key Takeaways
- The current list price of NDC 70860-0100 (Emgality) remains stable, supported by patent exclusivity and consistent demand.
- Competitive dynamics and reimbursement pressures suggest moderate price reductions may occur over the next few years, primarily driven by negotiated discounts.
- Patent expiration around 2028-2029 presents a critical inflection point; biosimilar entry could lead to significant price erosion.
- Growth in prescription volume driven by disease prevalence, expanded indications, and geographic expansion offers revenue opportunities despite pricing pressures.
- Stakeholders should monitor patent developments, biosimilar pipelines, and reimbursement policies to optimize strategic planning.
FAQs
1. When is patent expiration for NDC 70860-0100 (Emgality)?
Lilly’s patent protections for Emgality are expected to extend until approximately 2028, after which biosimilar competitors may enter the market.
2. How does the pricing of Emgality compare to other CGRP inhibitors?
Emgality’s list price (~$595 per dose) is comparable to Aimovig (~$575/month) and Ajovy (~$625/month). Vyepti has a slightly different pricing structure (~$400 per infusion).
3. What factors could lead to significant price reductions?
Introduction of biosimilars, increased market competition, payer-imposed discounts, and regulatory changes could drive substantial price erosion post-patent expiry.
4. Is there potential for price increases in the near future?
Given current market conditions, list prices are unlikely to increase significantly; any upward adjustments would depend on new indication approvals or formulation innovations.
5. How does demand for migraine treatments influence future pricing?
Rising prevalence of migraine, limited alternative therapies, and increasing awareness likely sustain demand, supporting stable prices—unless disrupted by biosimilar competition or market saturation.
References
[1] World Health Organization. (2019). Migraine Fact Sheet.
[2] IQVIA. (2022). Global Neurotherapeutic Market Report.
[3] FDA. (2018). Emgality (Galcanezumab) Prescribing Information.
[4] EvaluatePharma. (2022). Biologic Drug Pricing and Market Trends.
More… ↓
